Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:age_group |
50 years and older
|
| gptkbp:approves |
gptkb:2017
gptkb:FDA |
| gptkbp:booster_needed |
no
|
| gptkbp:clinical_trial |
Phase III trials
|
| gptkbp:clinical_use |
preventing shingles and postherpetic neuralgia
|
| gptkbp:community_health |
reduces healthcare costs
reduces incidence of shingles |
| gptkbp:contraindication |
severe allergic reaction to components
not for those with severe immunodeficiency |
| gptkbp:developed_by |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:dosage_form |
two doses
|
| gptkbp:formulation |
liquid suspension
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shingrix
|
| gptkbp:indication |
prevention of shingles
|
| gptkbp:injection_schedule |
0 and 2 to 6 months
|
| gptkbp:invention |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:is_effective_against |
over 90%
|
| gptkbp:is_recommended_by |
gptkb:CDC
gptkb:WHO |
| gptkbp:is_vulnerable_to |
gptkb:recombinant_zoster_vaccine
varies by location high immunogenicity covered by most insurance plans administered by healthcare professionals ongoing studies for long-term effects widely available in pharmacies store at 2° C to 8° C approved for adults developed to improve upon Zostavax effective against shingles recommended for immunocompetent adults remains high for several years significantly reduces shingles cases |
| gptkbp:marketed_as |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:provides_guidance_on |
included in vaccination schedules
|
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:safety_features |
well-studied
|
| gptkbp:side_effect |
fatigue
headache muscle pain fever pain at injection site generally mild |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
gptkb:herpes_zoster
|
| gptkbp:vaccine_awareness |
public health campaigns promote vaccination
|
| gptkbp:vaccine_category |
preventive vaccine
|
| gptkbp:vaccine_shelf_life |
36 months
|
| gptkbp:bfsParent |
gptkb:GSK
|
| gptkbp:bfsLayer |
4
|